# Tongshu Gene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tongshu-gene

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: tongshugene.net
- Total disclosed funding: $92M
- Latest round: Series D (Oct 14, 2024)
- Investors on record: 10

## About

Established in 2016 and based in Shanghai, China, Tongshu Gene is a technology company that focuses on tumour gene testing service, providing precise medication, efficacy monitoring, postoperative recurrence monitoring, risk prediction and other services. The company has set up medical clinical inspection centers, Gene Technology Research Institute and a production center in Shanghai and Changzhou, respectively. The CEO, Linghua Yan, is a Vice Chairman of China Genetic Testing Alliance. It self-developed microsatellite instability detection kit received the first Class III medical device registration certificate for MSI testing in January 2021. In June 2021, Tongshu Gene raised CNY 500 million in series C funding. In October 2024, it raised over CNY 100 million in series D funding.

Tongshu Gene has a full range of ctDNA detection technologies, including core technology packages such as cfTNA extraction, enrichment and PRIDE-cfDNA library building technology. Based on this, the company launched the tumour ctDNA detection platform Diagnostic Heart Safety, a ctDNA core technology systematic solution. It has also launched a microsatellite instability (MSI) detection kit. The company also developed the Oncology Speciality Internet Hospital, a health management platform that can provide video consultations.

The company generates revenue by providing tumour precision molecular diagnostic services and detection kits.

The company will use the sereis D funding to increase R&D investment, expand production scale, expand market channels and enhance brand influence.

## Funding rounds

- Series D, Oct 14, 2024, $14M — Broad Vision Funds, Jiangsu Jiandao Venture Capital
- Series C, Jun 16, 2021, $78M — GL Capital Group, Everest VC, Shenzhen Haichuang Fund Management, Oceanpine Capital, Jiangsu Tuobang Investment Management, Galaxy Yuanhui Investment, Broad Vision Funds, Jinyuan Capital
- Series B, Sep 22, 2020 — YuanBio Venture, Everest VC, Jiangsu Tuobang Investment Management

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series B
- Everest VC (https://capitalatlas.ai/funds/everest-vc) — Series B, Series C
- Jiangsu Tuobang Investment Management — Series B, Series C
- GL Capital Group (https://capitalatlas.ai/funds/gl-capital-group) — Series C
- Shenzhen Haichuang Fund Management — Series C
- Oceanpine Capital (https://capitalatlas.ai/funds/oceanpine-capital) — Series C
- Galaxy Yuanhui Investment — Series C
- Broad Vision Funds (https://capitalatlas.ai/funds/broad-vision-funds) — Series C, Series D
- Jinyuan Capital (https://capitalatlas.ai/funds/jinyuan-capital) — Series C
- Jiangsu Jiandao Venture Capital — Series D